Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

dc.contributor.author	Berenguer Berenguer, Juan
dc.contributor.author	González García, Juan
dc.contributor.author	Ribera Pascuet, Esteban
dc.contributor.author	Domingo Pedrol, Pere
dc.contributor.author	Santos González, Jesús
dc.contributor.author	Miralles Martín, Pilar
dc.contributor.author	Ribas del Blanco, María Ángeles
dc.contributor.author	Asensi Álvarez, Víctor
dc.contributor.author	Gimeno-Bayón Cobos, Juan Luis
dc.contributor.author	Pérez Molina, José Antonio
dc.contributor.author	Terrón Pernía, José Alberto
dc.contributor.author	Santamaría Jáuregui, Juan Miguel
dc.contributor.author	Pedrol Clotet, Enric
dc.date.accessioned	2013-01-30T10:24:00Z
dc.date.available	2013-01-30T10:24:00Z
dc.date.issued	2008
dc.identifier.citation	Clinical Infectious Diseases, 47(8), p. 1083-1092 (2008); doi:10.1086/592114	spa
dc.identifier.issn	1058-4838
dc.identifier.issn	1537-6591
dc.identifier.uri	http://hdl.handle.net/10651/11349
dc.format.extent	p. 1083-1092	spa
dc.language.iso	eng
dc.relation.ispartof	Clinical Infectious Diseases	spa
dc.rights	(c) Clinical Infectious Diseases
dc.source	WOK	spa
dc.title	Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903	spa
dc.type	journal article
dc.identifier.local	227	spa
dc.identifier.doi	10.1086/592114
dc.relation.publisherversion	http://dx.doi.org/10.1086/592114	spa

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.